Antibody responses to Moderna’s COVID-19 vaccine candidate, mRNA-1273, remained strong for almost 4 months following vaccination, data from a phase I trial indicated.
Serum neutralizing antibodies were detected in 34 healthy adult volunteers at day 119 following the first dose, and 90 days following the second dose, reported Alicia Widge, MD, of the National Institute of Allergy and Infectious Diseases (NIAID) in Bethesda, Maryland, and colleagues.
Moreover, both binding and neutralizing geometric mean titers exceeded those in 41 healthy controls who were recovering from COVID-19, the authors wrote in a Correspondence piece in the New England Journal of Medicine.
“Although correlates of protection against SARS-CoV-2 infection in humans are not yet established, these results show […] mRNA-1273 has the potential to provide durable humoral immunity,” the researchers wrote.
Importantly, they also found no new adverse events considered to be related to the vaccine after day 57.
Moderna recently made